---
document_datetime: 2025-09-02 13:50:40
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/nuvaxovid-epar-all-authorised-presentations_en.pdf
document_name: nuvaxovid-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.8436058
conversion_datetime: 2025-12-19 23:04:59.870465
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form      | Route of administration   | Immediate Packaging        | Content (concentration)   | Pack size                                |
|------------------|-------------------|------------|--------------------------|---------------------------|----------------------------|---------------------------|------------------------------------------|
| EU/1/21/1618/001 | Nuvaxovid         | --¹        | Dispersion for injection | Intramuscular use         | vial (glass)               | 5 mL (10 doses)           | 10 multidose vials (100 doses)           |
| EU/1/21/1618/002 | Nuvaxovid         | --¹        | Dispersion for injection | Intramuscular use         | vial (glass)               | 2.5 mL (5 doses)          | 10 multidose vials (50 doses)            |
| EU/1/21/1618/003 | Nuvaxovid         | --¹        | Dispersion for injection | Intramuscular use         | vial (glass)               | 5 mL (10 doses)           | 2 multidose vials (20 doses)             |
| EU/1/21/1618/004 | Nuvaxovid         | --¹        | Dispersion for injection | Intramuscular use         | vial (glass)               | 2.5 mL (5 doses)          | 2 multidose vials (10 doses)             |
| EU/1/21/1618/005 | Nuvaxovid XBB.1.5 | -- 2       | Dispersion for injection | Intramuscular use         | vial (glass)               | 0.5 mL (1 dose)           | 10 single dose vials (10 doses)          |
| EU/1/21/1618/006 | Nuvaxovid XBB.1.5 | -- 2       | Dispersion for injection | Intramuscular use         | vial (glass)               | 2.5 mL (5 doses)          | 10 multidose vials (50 doses)            |
| EU/1/21/1618/007 | Nuvaxovid JN.1    | -- 3       | Dispersion for injection | Intramuscular use         | vial (glass)               | 0.5 mL (1 dose)           | 10 single dose vials (10 doses)          |
| EU/1/21/1618/008 | Nuvaxovid XBB.1.5 | -- 2       | Dispersion for injection | Intramuscular use         | vial (glass)               | 2.5 mL (5 doses)          | 2 multidose vials (10 doses)             |
| EU/1/21/1618/009 | Nuvaxovid JN.1    | -- 3       | Dispersion for injection | Intramuscular use         | vial (glass)               | 0.5 mL (1 dose)           | 1 single dose vial (1 dose)              |
| EU/1/21/1618/010 | Nuvaxovid XBB.1.5 | -- 2       | Dispersion for injection | Intramuscular use         | vial (glass)               | 0.5 mL (1 dose)           | 1 single dose vial (1 dose)              |
| EU/1/21/1618/011 | Nuvaxovid JN.1    | -- 3       | Dispersion for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 mL (1 dose)           | 10 pre-filled syringes (10 doses)        |
| EU/1/21/1618/012 | Nuvaxovid JN.1    | -- 3       | Dispersion for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 mL (1 dose)           | 1 pre-filled syringe (1 dose)            |
| EU/1/21/1618/013 | Nuvaxovid JN.1    | -- 3       | Dispersion for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 mL (1 dose)           | 1 pre-filled syringe + 1 needle (1 dose) |

<div style=\"page-break-after: always\"></div>

--¹ One dose (0.5 mL) contains 5 micrograms of the of SARS-CoV-2 spike protein* and is adjuvanted with Matrix-M. Adjuvant Matrix-M containing per 0.5 mL dose: Fraction-A (42.5 micrograms) and Fraction-C (7.5 micrograms) of Quillaja saponaria Molina extract. * produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera frugiperda species. -- 2 One dose (0.5 mL) contains 5 micrograms of the of SARS-CoV-2 (Omicron XBB.1.5) spike protein* and is adjuvanted with Matrix-M. Adjuvant Matrix-M containing per 0.5 mL dose: Fraction-A (42.5 micrograms) and Fraction-C (7.5 micrograms) of Quillaja saponaria Molina extract. * produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera frugiperda species. -- 3 One dose (0.5 mL) contains 5 micrograms of the of SARS-CoV-2 (Omicron JN.1) spike protein* and is adjuvanted with Matrix-M. Adjuvant Matrix-M containing per 0.5 mL dose: Fraction-A (42.5 micrograms) and Fraction-C (7.5 micrograms) of Quillaja saponaria Molina extract. * produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera frugiperda species.